Multiple Myeloma Market Report by Drugs Types. Disease Types, End User, Countries and Companies Analysis 2026-2034

Multiple Myeloma Market Size and Forecast

The Multiple Myeloma Market is projected to grow from US$ 23.33 billion in 2025 to US$ 36.57 billion by 2034, registering a CAGR of 5.12% during 2026–2034. Market growth is supported by increasing awareness and diagnosis of multiple myeloma, continued advancements in targeted and personalized therapies, expanding clinical research and drug-development activities, and improving access to specialized oncology care. The growing adoption of innovative treatment approaches and ongoing investments in multiple myeloma research are further contributing to the market’s expansion over the forecast period.

What is Multiple Myeloma and Its Uses & Popularity Worldwide

Multiple myeloma is a hematological cancer characterized by the abnormal growth of plasma cells in the bone marrow, which can interfere with normal blood-cell production and cause complications involving bones, kidneys, immunity, and other organs. The disease is generally treated through combinations of drug therapies, immunotherapies, targeted treatments, stem-cell transplantation, and, for eligible patients with relapsed or refractory disease, advanced approaches such as CAR T-cell therapy and bispecific antibodies. Molecular and laboratory testing also plays an important role in diagnosis, disease classification, treatment selection, and monitoring. Multiple myeloma is most frequently diagnosed among older adults.

In the United States, the American Cancer Society estimates approximately 36,000 new cases and 10,850 deaths in 2026, with the average age at diagnosis around 69 years. The global market is gaining importance as healthcare systems expand access to hematology-oncology services and innovative therapies. Growing clinical research, increasing availability of targeted medicines, and improvements in long-term disease management are supporting demand for multiple myeloma diagnostics and treatments worldwide.

Number of People Diagnosed with Multiple Myeloma Worldwide by Region

• Asia: 73,870 cases, accounting for 39.3% of global multiple myeloma diagnoses.
• Europe: 50,092 cases, representing 26.7% of worldwide cases.
• Northern America: 37,050 cases, accounting for 19.7% of the global total.
• Latin America and the Caribbean: 15,194 cases, representing 8.1% of worldwide diagnoses.
• Africa: 8,978 cases, accounting for 4.8% of global cases.
• Oceania: 2,768 cases, representing approximately 1.5% of worldwide diagnoses.
• Worldwide: 187,952 new cases of multiple myeloma were estimated in 2022.

Growth Driver in the Market

Rising Disease Burden and Growing Demand for Oncology Treatment

The increasing number of people diagnosed with multiple myeloma is creating sustained demand for effective diagnostic and treatment options. Multiple myeloma predominantly affects older adults, and demographic aging is an important factor supporting the long-term need for specialized hematology and oncology care. In the United States alone, approximately 36,000 new multiple myeloma cases are expected in 2026, while about 10,850 deaths are projected from the disease. The average age at diagnosis is approximately 69 years, highlighting the strong association between disease burden and aging populations. In addition, improved diagnostic capabilities and greater awareness can increase identification of patients who previously may have remained undiagnosed or diagnosed at later stages. Multiple myeloma treatment commonly involves multiple lines of therapy because the disease can relapse after initial treatment. Consequently, increasing patient numbers, longer treatment journeys, and the need for maintenance and subsequent-line therapies are expanding the addressable market. Improvements in survival are also creating continued demand for therapies that can manage disease over extended periods.

Rapid Development of Targeted Therapies and Immunotherapies

Advancements in targeted therapies, immunotherapies, CAR T-cell treatments, and bispecific antibodies are significantly transforming the multiple myeloma treatment landscape. The FDA’s 2025 review of multiple myeloma therapies highlighted the introduction of several new treatment classes, including BCMA-directed CAR T-cell products and bispecific CD3 T-cell engagers, alongside established proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. In July 2025, the FDA granted accelerated approval to Lynozyfic (linvoseltamab-gcpt), a BCMA-directed bispecific antibody, for adults with relapsed or refractory multiple myeloma after at least four prior treatment lines. Further innovation continued in 2026, when the FDA approved a teclistamab-daratumumab combination for relapsed or refractory multiple myeloma after at least one prior line of therapy. These developments are expanding treatment choices and encouraging pharmaceutical companies to invest in new mechanisms, combination regimens, and earlier-line applications, supporting market growth.

Expansion of Precision Medicine and Improved Treatment Outcomes

The increasing emphasis on personalized treatment is another important growth driver for the multiple myeloma market. Modern management increasingly involves selecting therapies according to disease characteristics, previous treatment exposure, response, and specific molecular or cellular targets. BCMA-directed therapies are a major example of this trend, with CAR T-cell therapies and bispecific antibodies being incorporated into treatment strategies for appropriate patients. The FDA currently lists ABECMA (idecabtagene vicleucel) for adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, while CARVYKTI (ciltacabtagene autoleucel) is approved for certain patients after at least one prior line of therapy. The FDA has also reported substantial improvements in overall survival over recent decades, with median overall survival for newly diagnosed U.S. patients approaching 10 years according to its 2025 advisory materials. Longer survival increases the need for sequential therapies, monitoring, maintenance treatment, and management of relapse, thereby supporting sustained demand across the multiple myeloma treatment ecosystem.

Challenges in the Market

High Cost and Complexity of Advanced Multiple Myeloma Therapies

The high cost and clinical complexity associated with advanced multiple myeloma therapies remain important challenges for market expansion. Innovative treatments such as CAR T-cell therapies and bispecific antibodies require specialized healthcare infrastructure, trained medical personnel, patient monitoring, and appropriate management of potentially serious treatment-related adverse events. The FDA notes that CAR T-cell therapies have been associated with risks including cytokine release syndrome and neurological toxicities, requiring specialized safety management. Although the FDA eliminated REMS requirements for currently approved BCMA- and CD19-directed autologous CAR T-cell therapies in June 2025, treatment still requires sophisticated clinical capabilities and monitoring. These requirements can limit availability in healthcare systems where specialized oncology centers, cellular-therapy facilities, or trained professionals are limited. High treatment costs may also create affordability and reimbursement challenges, particularly in emerging markets. Consequently, unequal access to advanced therapies can slow adoption despite continuing innovation in the treatment landscape.

Disease Relapse and Treatment-Resistance Challenges

Multiple myeloma remains a long-term disease-management challenge because patients can experience relapse or become resistant to previously administered treatments. The FDA describes multiple myeloma as an incurable hematologic malignancy despite substantial advances in available therapies. As patients progress through successive lines of treatment, therapeutic options can become increasingly complex, requiring new mechanisms of action or combination strategies. This creates a continuing need for research into therapies capable of overcoming treatment resistance and achieving deeper, more durable responses. The development of new targeted therapies has expanded options for relapsed or refractory disease, but many newer treatments are initially indicated for patients who have already received several prior therapies. For example, the 2025 FDA approval of linvoseltamab targeted adults who had received at least four previous treatment lines. Similarly, BCMA-directed CAR T-cell therapies are used in specified relapsed or refractory populations. Managing relapse, resistance, treatment toxicity, and patient eligibility therefore remains a major clinical and commercial challenge.

Multiple Myeloma Treatment Launches Worldwide

• Iberdomide (Zenbexus) – Bristol Myers Squibb, United States (2026): The FDA granted accelerated approval in August 2026 for iberdomide in combination with daratumumab/hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who had received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
• Isatuximab-irfc (Sarclisa Escena) – Sanofi, United States (2026): In July 2026, the FDA approved a subcutaneous formulation of isatuximab-irfc for multiple myeloma indications, providing an additional administration option for patients receiving anti-CD38 therapy.
• Teclistamab (Tecvayli) + Daratumumab – Johnson & Johnson, United States (2026): In March 2026, the FDA approved teclistamab in combination with daratumumab/hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent.
• Daratumumab/hyaluronidase-fihj + VRd – Johnson & Johnson, United States (2026): The FDA approved this combination in January 2026 for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. In the CEPHEUS study, the combination produced a 52.3% minimal residual disease negativity rate, compared with 34.8% for VRd alone.
• Blenrep (belantamab mafodotin-blmf) + bortezomib/dexamethasone – GSK, United States (2025): The FDA approved Blenrep in October 2025 for adults with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
• Lynozyfic (linvoseltamab-gcpt) – Regeneron, United States (2025): The FDA granted accelerated approval in July 2025 for this BCMA-directed CD3 T-cell engager for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy. In the efficacy population, the objective response rate was 70%.
• Sarclisa (isatuximab-irfc) + VRd – Sanofi, United States (2024): In September 2024, the FDA approved isatuximab with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma in adults who were not eligible for autologous stem-cell transplantation. The IMROZ trial demonstrated a 40% reduction in the risk of disease progression or death compared with VRd alone.
• Darzalex Faspro + VRd – Johnson & Johnson, United States (2024): The FDA approved the combination in July 2024 for induction and consolidation treatment of newly diagnosed multiple myeloma in patients eligible for autologous stem-cell transplantation. The PERSEUS trial showed a 60% reduction in the risk of disease progression or death compared with VRd alone.
• Elrexfio (elranatamab-bcmm) – Pfizer, United States (2023): The FDA granted accelerated approval in August 2023 for this BCMA-directed CD3 T-cell engager for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody.
• Talvey (talquetamab-tgvs) – Johnson & Johnson, United States (2023): The FDA granted accelerated approval in August 2023 for this GPRC5D-directed CD3 T-cell engager for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy.

Chemotherapy Remains Important in Multi-Drug Treatment Regimens

The chemotherapy segment of the multiple myeloma market continues to play an important role, particularly as part of combination regimens, conditioning before autologous stem-cell transplantation, and treatment of patients with advanced or relapsed disease. Although newer targeted therapies and immunotherapies have reduced the relative reliance on traditional chemotherapy, cytotoxic agents remain relevant in selected patient populations. Real-world evidence shows that chemotherapy use has declined substantially over time as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and cellular therapies have expanded. In one long-term treatment analysis, chemotherapy accounted for 15.4% of treatment use in the most recent period examined, compared with substantially higher utilization historically. At the same time, multiple myeloma patients frequently require several treatment lines because the disease can relapse or become refractory. This creates continued demand for combination approaches and subsequent-line therapies. Growing global disease burden, with approximately 188,000 new multiple myeloma cases and 121,000 deaths estimated in 2022, supports ongoing treatment demand and preserves a role for chemotherapy within the broader therapeutic landscape.

Strong Adoption of Proteasome Inhibitors in Frontline and Relapsed Disease

The proteasome inhibitors market represents a major segment of multiple myeloma treatment because these medicines have become an established component of combination therapy across different stages of the disease. Key agents include bortezomib, carfilzomib, and ixazomib, which inhibit the proteasome and promote accumulation of abnormal proteins within malignant plasma cells, ultimately contributing to cancer-cell death. Bortezomib-based combinations remain particularly important in newly diagnosed disease, including regimens combining bortezomib with lenalidomide and dexamethasone. Real-world U.S. evidence involving 3,778 multiple myeloma patients found that 56.3% of patients in academic-care settings received proteasome inhibitors, demonstrating their continued clinical relevance. In a separate study of younger Indian patients, bortezomib, cyclophosphamide, and dexamethasone were used in 55% of cases, while bortezomib, lenalidomide, and dexamethasone were used in 38.5%. Increasing diagnosis, repeated treatment lines, combination therapy, and continuing demand for established treatment options are supporting the proteasome inhibitor segment worldwide.

Increasing Patient Pool and Need for Continuous Disease Management

The active multiple myeloma market encompasses patients requiring ongoing treatment for newly diagnosed, persistent, relapsed, or refractory disease. Unlike conditions treated with a short course of therapy, multiple myeloma commonly requires long-term management involving induction, consolidation, maintenance, and subsequent treatment lines. The continuing expansion of the active patient population is therefore generating sustained demand for pharmaceuticals, diagnostics, monitoring, supportive care, and specialized oncology services. Global estimates indicate that approximately 188,000 people were newly diagnosed with multiple myeloma in 2022, while 121,000 deaths were attributed to the disease. Importantly, researchers project that, if current incidence and mortality rates remain unchanged, global multiple myeloma incidence could increase by 71% by 2045 compared with 2022, reflecting population growth and aging. Treatment patterns are also becoming increasingly complex. Long-term real-world evidence indicates that the proportion of patients receiving at least three treatment lines increased from 26% during 1980–1989 to 56.2% during 2000–2009. These trends support continued expansion of the active disease-management market.

Hospitals as Key Centers for Specialized Multiple Myeloma Treatment

Hospitals represent a critical end-user segment in the multiple myeloma market because they provide comprehensive hematology-oncology services, chemotherapy and infusion facilities, diagnostic testing, stem-cell transplantation, supportive care, and access to advanced therapies. Academic hospitals and specialized cancer centers are particularly important for patients requiring autologous stem-cell transplantation, cellular therapies, clinical trials, and complex management of relapsed or refractory disease. A U.S. real-world study of 3,778 multiple myeloma patients found that most claims originated from community care settings, while academic centers had a higher proportion of stem-cell transplant claims, at 21.4% compared with 7.3% in community settings. The study also found that costs were generally higher in academic settings, reflecting their specialized services and complex patient populations. Hospitals are increasingly integrating multidisciplinary hematology teams, advanced diagnostics, infusion services, and cellular-therapy capabilities. As multiple myeloma patients require multiple lines of treatment and regular monitoring, hospitals and cancer centers are expected to remain important points of care throughout the disease-management pathway.

United States Advanced Oncology Infrastructure and Strong Adoption of Innovative Therapies

United States multiple myeloma market is supported by advanced oncology infrastructure, extensive clinical research, and rapid adoption of targeted therapies, immunotherapies, and cellular treatments. Multiple myeloma represents an important hematological cancer burden in the country, with the American Cancer Society estimating approximately 36,000 new cases and 10,850 deaths in 2026. The disease predominantly affects older adults: the average age at diagnosis is 69 years, while less than 1% of cases occur in people younger than 35. The lifetime risk remains below 1%, estimated at approximately 1 in 108 men and 1 in 133 women. The U.S. market also benefits from a strong ecosystem of pharmaceutical and biotechnology companies, academic cancer centers, and clinical-trial networks. Increasing use of proteasome inhibitors, monoclonal antibodies, bispecific antibodies, and CAR-T therapies is expanding treatment options. Continued investment in precision oncology and development of therapies for relapsed or refractory disease is expected to sustain demand for multiple myeloma diagnostics and treatment.

United Kingdom Rising Disease Burden and Expanding Access to Specialized Care

United Kingdom multiple myeloma market is supported by a well-established healthcare system, specialist hematology services, and increasing emphasis on early diagnosis and innovative cancer treatment. According to Cancer Research UK, approximately 6,532 people are diagnosed with myeloma each year in the UK, while around 3,200 deaths occur annually. Myeloma accounts for approximately 2% of all new cancer cases, with about 3,800 cases occurring in men and 2,800 in women each year. The disease is strongly associated with older age, with approximately 44% of new cases diagnosed in people aged 75 and over. Incidence rates have increased by approximately 37% since the early 1990s, demonstrating the continuing disease burden and need for specialized treatment. The UK market is further supported by research institutions, specialist cancer centers, and increasing adoption of targeted medicines and immunotherapies. Improvements in diagnostic pathways and treatment strategies, combined with ongoing clinical research into precision medicine and relapsed disease, are contributing to continued market development.

China Growing Disease Burden and Expansion of Modern Oncology Treatment

China multiple myeloma market is expanding alongside improvements in cancer diagnosis, healthcare infrastructure, and access to specialized hematology services. According to estimates based on the Global Burden of Disease 2021 database, China recorded approximately 17,250 new multiple myeloma cases and 12,984 deaths in 2021, with age-standardized incidence and mortality rates of 0.8 and 0.6 per 100,000 population, respectively. The same analysis reported that multiple myeloma incidence in China increased over the 1990–2021 period, while prevalence grew more rapidly, reflecting improvements in treatment and patient survival. Earlier national urban insurance data also showed that multiple myeloma incidence increased with age and was higher among men than women. Growing investment in oncology infrastructure and increasing availability of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and other advanced therapies are strengthening treatment capabilities. Pharmaceutical research and clinical trials are also expanding, particularly in major urban hospitals and specialized cancer centers. These developments are supporting greater adoption of modern multiple myeloma therapies across China’s healthcare system.

United Arab Emirates Healthcare Modernization and Increasing Demand for Specialized Oncology Services

United Arab Emirates multiple myeloma market is supported by healthcare infrastructure modernization, increasing investment in specialized cancer services, and expanding access to advanced diagnostic and therapeutic technologies. Data from the UAE National Cancer Registry for 2023 recorded 113 multiple myeloma cases among the Emirati population, including 94 male and 19 female patients. Across the broader UAE population, the registry reported multiple myeloma as a recognized hematological malignancy requiring specialist cancer care. The UAE’s healthcare system has increasingly focused on improving cancer diagnosis, treatment quality, and access to advanced oncology services. Major hospitals and specialist centers provide hematology, chemotherapy, transplantation, and modern targeted-treatment capabilities, while international healthcare partnerships support technology and knowledge transfer. Growing awareness of cancer, development of precision-medicine capabilities, and increasing availability of biologics and immunotherapies are supporting the evolution of the market. The country’s strong private healthcare sector and medical-tourism infrastructure also contribute to demand for sophisticated cancer services. Continued investment in specialized oncology infrastructure is expected to strengthen access to multiple myeloma diagnosis, treatment, and long-term disease management.

Multiple Myeloma Market Segments

Drugs Types

• Chemotherapy
• Protease Inhibitors
• Monoclonal Antibody
• Others

Disease Types

• Active multiple myeloma
• Smoldering multiple myeloma

End User

• Hospitals
• Clinics
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• Novartis AG
• Abbvie Inc.
• Sanofi
• Johnson and Johnson
• Baxter International Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd
• Bristol-Myers Squibb Company

Report Details: